Clinigen Group (LON:CLIN) target held steady at 1,000.00GBX, reported today by Peel Hunt
- Updated: September 27, 2016
Clinigen Group (LON:CLIN) had its price target hold steady to 1,000.00GBX by Peel Hunt in an issued report announced 9/28/2016. The latest target price indicates remote upside the company's last stock close price.
On 07/20/2016, numis released a statement for Clinigen Group (LON:CLIN) bumped up the target price from 0.00GBX to 916.00GBX. At the time, this suggested an upside of 0.34%.
Showing a price of 0.00GBX, Clinigen Group (LON:CLIN) traded -1.31% lower on the day. The last closing price is down 13.51% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. CLIN has recorded a 50-day average of 651.96GBX and a two hundred day moving average of 596.84GBX. 228,982 shares of the stock were exchanged, down from an avg. volume of 496,983
See Chart Below
With a total market value of 0 GBX, Clinigen Group has one year low of 492.75GBX and a one year high of 723.50GBX .
In addition to Peel Hunt reporting its stock price target, a total of 5 brokerages have issued a ratings update on the stock. The consensus target price is 850.00GBX with 3 equity analysts rating the company a strong buy, two analysts rating the company a buy, zero analysts rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.
Brief Synopsis About Clinigen Group (LON:CLIN)
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP). The CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. The MA segment specializes in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies. The GA segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these often-essential drugs. The SP segment manufactures and distributes its own and in-license specialist, hospital-only medicines.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.